首页|Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Aim: M701 is a bispecific CD3/EpCAM T-cell engager antibody to treat malignant ascites. This study aimed to predict in vivo exposure-cytotoxicity relationship and human pharmacokinetics (PK) characteristics of M701, as well as to design optimal starting dose and effective dose for M701 first-in-human (FIH) study.
Bispecific T cell engager antibodyPharmacokinetics/pharmacodynamicsTranslational predictionSynapse-based cell killingFirst-in-human
NSTL
Elsevier
